Rivaroxaban: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
'''''For patient information, click <u>[[Rivaroxaban (patient information)|here]]'''''</u>. | '''''For patient information, click <u>[[Rivaroxaban (patient information)|here]]'''''</u>. | ||
{{SB}} | {{SB}} XARELTO<sup>®</sup> | ||
==Overview== | ==Overview== | ||
Revision as of 19:56, 6 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
For patient information, click here. Synonyms / Brand Names: XARELTO®
Overview
Category
FDA Package Insert
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages